Synonyms ALX, ALXR, FMLP-R-I + [16] |
Introduction Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophil chemotactic factors (PubMed:1374236). Binding of FMLP to the receptor causes activation of neutrophils (PubMed:1374236). This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:1374236). The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of pro-inflammatory signals such as LTB4 (leukotriene B4) (PubMed:9547339). Receptor for the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-induced osteoclast differentiation (By similarity). Acts as a receptor for humanin (PubMed:15465011). |
Target |
Mechanism FPR2 modulators |
Active Org. ResoTher Pharma ASStartup |
Originator Org. ResoTher Pharma ASStartup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism ANXA1 agonists [+1] |
Active Org. Emergo Therapeutics, Inc.Startup |
Originator Org. Emergo Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism FPR2 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date16 Sep 2024 |
Sponsor / Collaborator- |
Start Date30 Jun 2024 |
Sponsor / Collaborator ResoTher Pharma ASStartup |
Start Date01 Apr 2021 |
Sponsor / Collaborator |